Company intelligence / Profile preview

Aspen Creek

Cambridge, Massachusetts, United States

Ownership: Private
Development stage: Other

Overview

Aspen Creek Therapeutics is an early-stage biotechnology company focused on developing next-generation precision medicines, particularly in the field of oncology. The company leverages a proprietary targeted protein degradation platform to design small molecules that can selectively eliminate disease-causing proteins. By focusing on targets that were previously considered undruggable, Aspen Creek aims to create highly specific therapies with improved efficacy and reduced toxicity for cancer patients. The company operates primarily in a stealth or early-development mode, backed by venture capital investment.

Therapeutic areas: Oncology
Modalities: Small moleculeProteolysis-targeting chimera therapy
Industry: Biotech

Beyond the preview

Go deeper on Aspen Creek.

Explore clinical development, deal activity, and the competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from trial design and recruitment through results.

Trial phase
Status
Readouts

Licensing & deals

Explore licensing agreements, acquisitions, and the assets behind each deal.

Partners
Deal terms
Milestones

Funding history

Trace financing activity and the investors behind a company’s development.

Funding rounds
Investors
Capital raised

Competitive landscape

Compare peer pipelines by target, modality, and therapeutic area.

Peer companies
Targets
Pipeline overlap

Technologies & patents

Explore technology platforms and the patent landscape around relevant assets.

Platforms
Patents
Assignees

Research & analysis

Connect company news and source material to the questions you’re investigating.

Company news
Sources
Analysis

Bring the full picture into focus.

See how Gosset can support your research on Aspen Creek.

Explore the full profile